Impact of GLA Variant Classification on the Estimated Prevalence of Fabry Disease : A Systematic Review and Meta-Analysis of Screening Studies
BACKGROUND: The diagnosis of Fabry disease (FD) has relevant implications related to the management. Thus, a clear assignment of GLA variant pathogenicity is crucial. This systematic review and meta-analysis aimed to investigate the prevalence of FD in high-risk populations and newborns and evaluate the impact of different GLA variant classifications on the estimated prevalence of FD.
METHODS: We searched the EMBASE and PubMed databases on February 21, 2023. Observational studies evaluating the prevalence of FD and reporting the identified GLA variants were included. GLA variants were re-evaluated for their pathogenicity significance using the American College of Medical Genetics and Genomics criteria and the ClinVar database. The pooled prevalence of FD among different settings was calculated. The study was registered on PROSPERO (CRD42023401663) and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines.
RESULTS: Of the 3941 studies identified, 110 met the inclusion criteria. The pooled prevalence of FD was significantly different according to the clinical setting and criteria used for the pathogenicity assessment. Using the American College of Medical Genetics and Genomics criteria, the pooled prevalence was 1.2% in patients with left ventricular hypertrophy/hypertrophic cardiomyopathy (26 studies; 10 080 patients screened), 0.3% in end-stage renal disease/chronic kidney disease (38 studies; 62 050 patients screened), 0.7% in stroke (25 studies; 15 295 patients screened), 0.7% in cardiac conduction disturbance requiring pacemaker (3 studies; 1033 patients screened), 1.0% in small-fiber neuropathy (3 studies; 904 patients screened), and 0.01% in newborns (15 studies; 11 108 793 newborns screened). The pooled prevalence was different if the GLA variants were assessed using the ClinVar database, and most patients with a discrepancy in the pathogenicity assignment carried 1 of the following variants: p.A143T, p.D313Y, and p.E66Q.
CONCLUSIONS: This systematic review and meta-analysis describe the prevalence of FD among newborns and high-risk populations, highlighting the need for a periodic reassessment of the GLA variants in the context of recent clinical, biochemical, and histological data.
REGISTRATION: URL: https://crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42023401663.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Circulation. Genomic and precision medicine - 16(2023), 6 vom: 04. Dez., Seite e004252 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Monda, Emanuele [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alpha-Galactosidase |
|---|
| Anmerkungen: |
Date Completed 21.12.2023 Date Revised 21.12.2023 published: Print-Electronic ClinicalTrials.gov: CRD42023401663 Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCGEN.123.004252 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365383236 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365383236 | ||
| 003 | DE-627 | ||
| 005 | 20231227135426.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCGEN.123.004252 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1234.xml |
| 035 | |a (DE-627)NLM365383236 | ||
| 035 | |a (NLM)38047356 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Monda, Emanuele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of GLA Variant Classification on the Estimated Prevalence of Fabry Disease |b A Systematic Review and Meta-Analysis of Screening Studies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2023 | ||
| 500 | |a Date Revised 21.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: CRD42023401663 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The diagnosis of Fabry disease (FD) has relevant implications related to the management. Thus, a clear assignment of GLA variant pathogenicity is crucial. This systematic review and meta-analysis aimed to investigate the prevalence of FD in high-risk populations and newborns and evaluate the impact of different GLA variant classifications on the estimated prevalence of FD | ||
| 520 | |a METHODS: We searched the EMBASE and PubMed databases on February 21, 2023. Observational studies evaluating the prevalence of FD and reporting the identified GLA variants were included. GLA variants were re-evaluated for their pathogenicity significance using the American College of Medical Genetics and Genomics criteria and the ClinVar database. The pooled prevalence of FD among different settings was calculated. The study was registered on PROSPERO (CRD42023401663) and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines | ||
| 520 | |a RESULTS: Of the 3941 studies identified, 110 met the inclusion criteria. The pooled prevalence of FD was significantly different according to the clinical setting and criteria used for the pathogenicity assessment. Using the American College of Medical Genetics and Genomics criteria, the pooled prevalence was 1.2% in patients with left ventricular hypertrophy/hypertrophic cardiomyopathy (26 studies; 10 080 patients screened), 0.3% in end-stage renal disease/chronic kidney disease (38 studies; 62 050 patients screened), 0.7% in stroke (25 studies; 15 295 patients screened), 0.7% in cardiac conduction disturbance requiring pacemaker (3 studies; 1033 patients screened), 1.0% in small-fiber neuropathy (3 studies; 904 patients screened), and 0.01% in newborns (15 studies; 11 108 793 newborns screened). The pooled prevalence was different if the GLA variants were assessed using the ClinVar database, and most patients with a discrepancy in the pathogenicity assignment carried 1 of the following variants: p.A143T, p.D313Y, and p.E66Q | ||
| 520 | |a CONCLUSIONS: This systematic review and meta-analysis describe the prevalence of FD among newborns and high-risk populations, highlighting the need for a periodic reassessment of the GLA variants in the context of recent clinical, biochemical, and histological data | ||
| 520 | |a REGISTRATION: URL: https://crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42023401663 | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Fabry disease | |
| 650 | 4 | |a galactosidases | |
| 650 | 4 | |a globotriaosylceramide | |
| 650 | 4 | |a humans | |
| 650 | 4 | |a prevalence | |
| 650 | 7 | |a alpha-Galactosidase |2 NLM | |
| 650 | 7 | |a EC 3.2.1.22 |2 NLM | |
| 700 | 1 | |a Diana, Gaetano |e verfasserin |4 aut | |
| 700 | 1 | |a Graziani, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Rubino, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Bakalakos, Athanasios |e verfasserin |4 aut | |
| 700 | 1 | |a Linhart, Ales |e verfasserin |4 aut | |
| 700 | 1 | |a Germain, Dominique P |e verfasserin |4 aut | |
| 700 | 1 | |a Scarpa, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Biagini, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Pieroni, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Elliott, Perry Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Limongelli, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation. Genomic and precision medicine |d 2018 |g 16(2023), 6 vom: 04. Dez., Seite e004252 |w (DE-627)NLM280989210 |x 2574-8300 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:6 |g day:04 |g month:12 |g pages:e004252 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCGEN.123.004252 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 6 |b 04 |c 12 |h e004252 | ||